Provectus Pharmaceuticals, Inc. (PVCT.OB) is “One to Watch”
Provectus Pharmaceuticals is focused on developing advanced therapies designed to target and destroy the deadliest cancer as well as developing groundbreaking biotechnologies to augment vaccine production and detect viruses. The company is currently conducting clinical trials on their two proprietary drugs, Provecta and Xantryl. Provectra is unique from other cancer treatments by concentrating on toxic levels of tissue while avoiding healthy tissue consequently making it safer and more effective than conventional therapies such as chemotherapy and radiation. The drug is targeting melanoma and focal tumors of the breast, liver and prostate, which together account for more than 520,000 new cases…